Form 8-K - Current report:
SEC Accession No. 0001193125-20-044757
Filing Date
2020-02-21
Accepted
2020-02-21 16:19:54
Documents
18
Period of Report
2020-02-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d894000d8k.htm   iXBRL 8-K 40511
2 EX-1.1 d894000dex11.htm EX-1.1 132936
3 EX-4.2 d894000dex42.htm EX-4.2 254207
4 EX-5.1 d894000dex51.htm EX-5.1 18346
9 GRAPHIC g894000img1.jpg GRAPHIC 7801
10 GRAPHIC g894000img2.jpg GRAPHIC 5892
  Complete submission text file 0001193125-20-044757.txt   726049

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA amgn-20200221.xsd EX-101.SCH 4548
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE amgn-20200221_def.xml EX-101.DEF 13774
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE amgn-20200221_lab.xml EX-101.LAB 22822
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amgn-20200221_pre.xml EX-101.PRE 14743
16 EXTRACTED XBRL INSTANCE DOCUMENT d894000d8k_htm.xml XML 6351
Mailing Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Business Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (805)447-1000
AMGEN INC (Filer) CIK: 0000318154 (see all company filings)

EIN.: 953540776 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37702 | Film No.: 20640290
SIC: 2836 Biological Products, (No Diagnostic Substances)